Oncologix Tech Inc.
company.status.inactiveCIK 799694fmd_01KMCWMJG34QQ0DY1MGB7ZRVRCManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Sep 01, 2010 to May 31, 2015, 19 periods
Latest annual · FY2014
Millions- Total revenues
- 4
- Gross profit
- 1
- Operating income
- (1)
- Net income
- (1)
- Free cash flow
- (1)
Latest quarter · Q3 FY2015
Millions- Total revenues
- 1
- Gross profit
- 0
- Operating income
- (0)
- Free cash flow
- (0)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2011 to FY2014
- n/m
Oncologix Tech Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2014 | FY2013 | Change | Source |
|---|---|---|---|---|
| Revenue | $3.7 million | $244,246 | +1,405.6% | 10-K 2014-12-11 · proof |
| Gross profit | $614,411 | $48,547 | +1,165.6% | 10-K 2014-12-11 · proof |
| Operating income | -$571,839 | -$286,575 | 10-K 2014-12-11 · proof | |
| Net income | -$1.3 million | -$653,459 | 10-K 2014-12-11 · proof | |
| Cash from operating activities | -$629,942 | -$105,817 | 10-K 2014-12-11 · proof | |
| Free cash flow | -$629,064 | 10-K 2014-12-11 · proof | ||
| Total assets | $2.1 million | $2 million | +5% | 10-K 2014-12-11 · proof |
| Total liabilities | $2.8 million | $2.4 million | +16.9% | 10-K 2014-12-11 · proof |
| Cash and cash equivalents | $17,504 | $39,456 | -55.6% | 10-K 2014-12-11 · proof |
- What was Oncologix Tech Inc.'s revenue in fiscal 2014?
- Oncologix Tech Inc. reported revenue of $3.7 million for fiscal 2014 (the year ended Aug 31, 2014), against $244,246 the year before (+1,405.6%). Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What was Oncologix Tech Inc.'s gross profit in fiscal 2014?
- Oncologix Tech Inc. reported gross profit of $614,411 for fiscal 2014 (the year ended Aug 31, 2014), against $48,547 the year before (+1,165.6%). Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What was Oncologix Tech Inc.'s operating income in fiscal 2014?
- Oncologix Tech Inc. reported operating income of -$571,839 for fiscal 2014 (the year ended Aug 31, 2014), against -$286,575 the year before. Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What was Oncologix Tech Inc.'s net income in fiscal 2014?
- Oncologix Tech Inc. reported net income of -$1.3 million for fiscal 2014 (the year ended Aug 31, 2014), against -$653,459 the year before. Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What was Oncologix Tech Inc.'s cash from operating activities in fiscal 2014?
- Oncologix Tech Inc. reported cash from operating activities of -$629,942 for fiscal 2014 (the year ended Aug 31, 2014), against -$105,817 the year before. Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What was Oncologix Tech Inc.'s free cash flow in fiscal 2014?
- Oncologix Tech Inc. reported free cash flow of -$629,064 for fiscal 2014 (the year ended Aug 31, 2014). Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What are Oncologix Tech Inc.'s total assets?
- As of Aug 31, 2014, Oncologix Tech Inc. reported total assets of $2.1 million, against $2 million a year earlier (+5%). Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What are Oncologix Tech Inc.'s total liabilities?
- As of Aug 31, 2014, Oncologix Tech Inc. reported total liabilities of $2.8 million, against $2.4 million a year earlier (+16.9%). Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
- What are Oncologix Tech Inc.'s cash and cash equivalents?
- As of Aug 31, 2014, Oncologix Tech Inc. reported cash and cash equivalents of $17,504, against $39,456 a year earlier (-55.6%). Source: the 10-K filed with the SEC on Dec 11, 2014. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:799694&period_type=annual&limit=5"Information only, not investment advice.